Yantai Dongcheng Pharmaceutical GroupLtd Valuation

Q: What is the Fair Price of 002675 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002675 (CN¥12.83) is trading above our estimate of [[fair value]] (CN¥2.35)

Is 002675 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002675 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002675 (CN¥12.83) is trading above our estimate of fair value (CN¥2.35)

Significantly Below Fair Value: 002675 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002675?

Key metric: As 002675 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002675. This is calculated by dividing 002675's market cap by their current earnings.
What is 002675's PE Ratio?
PE Ratio	116.5x
Earnings	CN¥90.79m
Market Cap	CN¥10.58b

002675 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4x
Enterprise Value/EBITDA	30.2x
PEG Ratio	2.6x

Price to Earnings Ratio vs Peers

How does 002675's PE Ratio compare to its peers?

The above table shows the PE ratio for 002675 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	58.9x
688739 Liaoning Chengda BiotechnologyLtd	33.4x	n/a	CN¥10.9b
301207 Hualan Biological Vaccine	23.1x	33.3%	CN¥11.4b
002038 Beijing SL Pharmaceutical	94.3x	n/a	CN¥7.4b
300294 China Resources Boya Bio-pharmaceutical GroupLtd	85x	44.4%	CN¥15.6b
002675 Yantai Dongcheng Pharmaceutical GroupLtd	116.5x	45.3%	CN¥10.6b

Price-To-Earnings vs Peers: 002675 is expensive based on its Price-To-Earnings Ratio (116.5x) compared to the peer average (57.4x).

Price to Earnings Ratio vs Industry

How does 002675's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002675 is expensive based on its Price-To-Earnings Ratio (116.5x) compared to the CN Biotechs industry average (36x).

Price to Earnings Ratio vs Fair Ratio

What is 002675's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002675 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	116.5x
Fair PE Ratio	39.3x

Price-To-Earnings vs Fair Ratio: 002675 is expensive based on its Price-To-Earnings Ratio (116.5x) compared to the estimated Fair Price-To-Earnings Ratio (39.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002675 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥12.83	CN¥15.25 +18.9%	8.2%	CN¥16.50	CN¥14.00	n/a	2
Nov ’25	CN¥12.95	CN¥15.25 +17.8%	8.2%	CN¥16.50	CN¥14.00	n/a	2
Oct ’25	CN¥14.10	CN¥15.25 +8.2%	8.2%	CN¥16.50	CN¥14.00	n/a	2
Jun ’25	CN¥14.65	CN¥19.90 +35.8%	10.6%	CN¥22.00	CN¥17.80	n/a	2
May ’25	CN¥13.83	CN¥20.30 +46.8%	8.4%	CN¥22.00	CN¥18.60	n/a	2
Apr ’25	CN¥13.89	CN¥20.30 +46.1%	8.4%	CN¥22.00	CN¥18.60	n/a	2
Mar ’25	CN¥15.12	CN¥20.30 +34.3%	8.4%	CN¥22.00	CN¥18.60	n/a	2
Feb ’25	CN¥14.16	CN¥20.30 +43.4%	8.4%	CN¥22.00	CN¥18.60	n/a	2
Jan ’25	CN¥18.33	CN¥20.30 +10.7%	8.4%	CN¥22.00	CN¥18.60	n/a	2
Dec ’24	CN¥17.76	CN¥20.30 +14.3%	8.4%	CN¥22.00	CN¥18.60	n/a	2
Nov ’24	CN¥18.51	CN¥20.30 +9.7%	8.4%	CN¥22.00	CN¥18.60	CN¥12.95	2
Oct ’24	CN¥16.63	CN¥20.30 +22.1%	8.4%	CN¥22.00	CN¥18.60	CN¥14.10	2
Sep ’24	CN¥14.17	CN¥20.30 +43.3%	8.4%	CN¥22.00	CN¥18.60	CN¥11.93	2
Aug ’24	CN¥14.85	CN¥20.95 +41.1%	5.0%	CN¥22.00	CN¥19.90	CN¥12.44	2
Jul ’24	CN¥14.71	CN¥20.95 +42.4%	5.0%	CN¥22.00	CN¥19.90	CN¥12.58	2
Jun ’24	CN¥15.37	CN¥20.95 +36.3%	5.0%	CN¥22.00	CN¥19.90	CN¥14.65	2

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.66

2.6%

14.2%

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

-0.4%

15.5%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.2b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

-5.1%

14.5%